Scotia Capital’s Merck MRK Stock Holding History

Scotia Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-209,600	Closed	-$11.4M	–	820
2015 Q2	$11.4M	Buy	+209,600	New	+$11.8M	0.23%	83

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Scotia Capital's MRK Position: Q2 2026 in Review

Scotia Capital reduced its Merck (MRK) stake by 8.3% in Q2 2026, selling an estimated $1.96M and leaving 185,895 shares worth $23.9M. The position accounts for 0.09% of the portfolio, ranked #131.

Scotia Capital first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $46.8M in Q4 2022. 3,834 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Scotia Capital held 185,895 shares of Merck worth $23.9M as of Q2 2026.
Scotia Capital sold 16,772 Merck shares in Q2 2026, an estimated $1.96M.
Merck made up 0.09% of Scotia Capital's portfolio in Q2 2026, its #131 holding.
Scotia Capital first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
Scotia Capital's Merck position peaked at $46.8M in Q4 2022.
3,834 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.